AbbVie (ABBV)

These stocks check off multiple boxes for income investors.

AbbVie’s first quarter results for 2026 exceeded management’s guidance midpoint and internal expectations, with adjusted earnings per share and revenue comin...

By holding these top income stocks in your portfolio, you can have a position in some great companies while also generating cash flow each month.

But is the stock a buy on the dip?

These stocks offer high yields, attractive valuations, significant upside, and can be terrific investments to buy right now.

The timing is great for scooping up shares of these well-run companies.

Pharmaceutical company AbbVie (NYSE:ABBV) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.8% year on year to $13.98 billion. Its non-G...

Sonoco Products Company delivers packaging solutions to global consumer and industrial markets, with a reported dividend yield of 4.2%.

What Happened? Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.5% in the afternoon session after the company reported first-quarter results that...

AbbVie (ABBV) Q1 2026 Earnings Transcript

Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q1 CY2026, with sales up 12.4% year on year to $15 billion. Its non-GAAP ...

Mind your investment horizon.

Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Wednesday before market hours. Here’s what to expect. AbbVie beat analysts...

This pharma stock is cheap for a reason.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stoc...

Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks?

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

These stocks pay juicy dividends but also offer much more.

These stocks are keepers.

Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and Reclaiming Your Life.

The pharma giant is still a rock-solid dividend stock.